Search

Your search keyword '"Drug therapy, Combination"' showing total 318,783 results
Start Over Descriptor "Drug therapy, Combination"
318,783 results on '"Drug therapy, Combination"'

1. Arzneitherapie des Diabetes mellitus Typ 2 – ist Metformin neuerdings verzichtbar?

Author

Gallwitz, Baptist

Abstract

Copyright of Innere Medizin (2731-7080) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

2. USE OF DECELLULARIZED HUMAN AMNIOTIC MEMBRANE IN INTESTINAL ANASTOMOSES: A STUDY IN RATS TREATED WITH 5-FLUOROURACIL

Author

Daniel Dantas FERRARIN, Osvaldo MALAFAIA, Nicolau Gregori CZECZKO, Luiz Fernando KUBRUSLY, Marcos Fabiano SIGWALT, Eros Luiz de SOUSA, João Carlos Domingues REPKA, and Pedro Henrique Lambach CARON

Subjects
Amnion, Surgical Anastomosis, Drug Therapy, Combination, Membranes, Surgery, RD1-811, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

ABSTRACT BACKGROUND: Nowdays, more relevant applications of perinatal derivatives, such as amniotic membrane (AM), are emerging in our environment as a source of biomaterials for use in different healing processes. The study of anastomosis healing associated with antimetabolic drugs such as 5-fluorouracil (5-FU) is a potential target of AM. AIMS: To evaluate the healing effects of AM in rats treated with 5-FU at a dose of 20 mg/kg on the seventh day of postoperative evolution, regarding the parameters percentage of type I collagen (mature), cell viability, microvascular density and formation of granulation tissue. METHODS: Thirty-two Wistar rats were used, submitted to colotomy and colorraphy, separated into four groups of eight, which received different treatments daily, intraperitoneally, until the day of sacrifice: saline solution (C), 20 mg/kg 5-FU, 20 mg/kg 5-FU and AM. RESULTS: Treatment with 20 mg/kg of 5-FU, on the seventh postoperative day, induced adverse effects on the anastomotic healing process, evidenced by a decrease in the percentage of type I (mature) collagen, cell viability, microvascular density, fibrin-leukocyte scab formation and angiofibroblast proliferation; the use of AM under these conditions induced an improvement in the percentage of type I (mature) collagen. CONCLUSIONS: Treatment with 20 mg/kg of 5-FU on the seventh postoperative day induced adverse effects on the anastomotic healing process, and the use of AM under these conditions induced an improvement in the percentage of type I (mature) collagen.

Published
2024
Full Text
View/download PDF

3. Recent Findings from Shandong First Medical University Highlight Research in Carcinomas (Targeted combination chemotherapy effective in nuclear protein in testis carcinoma of lung origin: A case report and review of the literature)

Subjects
Drug therapy, Combination, Squamous cell carcinoma -- Care and treatment, Chemotherapy, Cancer -- Chemotherapy, Physical fitness
Abstract

2025 JAN 18 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on carcinomas are presented in a new report. According to [...]

Published
2025

6. Merck to discontinue phase 3 KeyVibe-003 & KeyVibe-007 trials of vibostolimab and favezelimab FDCs with pembrolizumab in certain patients with NSCLC

Subjects
Merck Research Laboratories, Drug therapy, Combination, Pemetrexed, Lung cancer, Non-small cell, Bendamustine, Pharmaceuticals and cosmetics industries, Keytruda (Medication)
Abstract

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody. Vibostolimab [...]

Published
2024

9. NPPA revises draft working sheet for Glenmark's cardiovascular drug following review order

Subjects
Price fixing, Cardiovascular agents -- Prices and rates, Drug therapy, Combination, Goods and services tax, Telmisartan -- Prices and rates, Company pricing policy, Pharmaceuticals and cosmetics industries
Abstract

Byline: Gireesh Babu The National Pharmaceutical Pricing Authority (NPPA) has revised the draft working sheet for retail price fixation of Glenmark Pharmaceuticals' cardiovascular drug combination cilnidipine 20 mg and telmisartan [...]

Published
2024

11. New Findings from Uppsala University in the Area of Antimicrobial Chemotherapy Published [Therapeutic drug monitoring (TDM) of b-lactam/b-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study]

Subjects
Uppsala University, Drug therapy, Combination, Antibacterial agents, Chemotherapy, Cancer -- Chemotherapy, Physical fitness
Abstract

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on antimicrobial chemotherapy have been presented. According to news originating [...]

Published
2024

12. Data on Dyslipidemias Discussed by Researchers at I.M. Sechenov First Moscow State Medical University (Optimal treatment strategies in comorbid patients with hypertension and dyslipidemia: the role of fixed-dose combinations)

Subjects
Comorbidity -- Care and treatment, Drug therapy, Combination, Physical fitness, Hypertension -- Care and treatment
Abstract

2024 NOV 9 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on dyslipidemias have been presented. According to news originating from [...]

Published
2024

14. Tramadol and Paracetamol Fixed Combination in a Portuguese Primary Care Unit: A Cross-Sectional Study

Author

Bruno Pedrosa, Catarina Santos, Marília Martins, Fábio Gouveia, Fátima Franco, Margarida Vardasca, and Jorge Nogueira

Subjects
Acetaminophen, Chronic Pain, Drug Therapy, Combination, Primary Health Care, Tramadol, Medicine, Medicine (General), R5-920
Abstract

Introduction: Tramadol/paracetamol combination is one of the most prescribed pain medications in Portugal. At the Regional Health Administration of Lisbon and Tagus Valley, 1 119 229 packages of tramadol/paracetamol were prescribed for 12 months, corresponding to the second most prescribed analgesic. We ask whether this drug is prescribed for acute and irruptive pain or if it is prescribed as a long-term treatment for chronic pain. Methods: This cross-sectional study describes the prescription of tramadol/paracetamol in a Portuguese primary care unit. The population studied corresponds to the 344 patients who received a tramadol/paracetamol prescription between July 2020 and June 2021. Results: In this period, a total of 687 prescriptions were made, corresponding to 2500 packages of tramadol/paracetamol, of which 1874 were bought. There was no statistically significant difference between the number of packages bought over the 4 trimesters (p = 0.275) and 35.3% of the patients bought this medication in more than one trimester. We found that 16.5% bought tramadol/paracetamol in an amount that allows a use of more than 90 days. Conclusion: This demonstrates that the tramadol/paracetamol combination plays a central role in the treatment of pain and that a significant percentage of patients use this medication chronically, questioning the adequacy of this therapy in these patients. However, larger studies that assess pain control are needed to support the results presented in this work.

Published
2024

15. Development of Mini-Tablet and Multi-Unit Pellet Systems: Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles

Author

Challener, Cynthia A.

Subjects
Patient compliance, Drug therapy, Combination, Coatings -- Product introduction, Business, Pharmaceuticals and cosmetics industries
Abstract

Multi-unit pellet systems (MUPS) and intelligently encapsulated mini-tablet systems (EMTS) have unique combinations of advantages compared to conventional oral formulations. The drug release from MUPS and EMTS can be modified [...]

Published
2024

16. Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis

Author

Ji Soo Kim, Gyeongsil Lee, Kyung-Il Park, and Seung-Won Oh

Subjects
diabetes mellitus, type 2, drug therapy, combination, hypoglycemic agents, stroke, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Background There is still a lack of research on which diabetic drugs are more effective in preventing stroke. Our network metaanalysis aimed to compare cerebrovascular benefits among glucose-lowering treatments. Methods We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, and the ClinicalTrials.gov registry for clinical trials from inception through May 25, 2021. We included both prespecified cerebrovascular outcomes and cerebrovascular events reported as severe adverse events. Subgroup analyses were conducted by stroke subtype, publication type, age of patients, baseline glycosylated hemoglobin (HbA1c), duration of type 2 diabetes mellitus, and cardiovascular risks. Results Of 2,861 reports and 1,779 trials screened, 79 randomized controlled trials comprising 206,387 patients fulfilled the inclusion criteria. In the pairwise meta-analysis, the use of glucagon-like peptide-1 (GLP-1) agonist was associated with a lower risk of total stroke compared with placebo (relative risk [RR], –0.17; 95% confidence interval [CI], –0.27 to –0.07). In the network meta-analysis, only the use of sodium-glucose cotransporter-2 (SGLT-2) inhibitor was associated with a reduction of total stroke, compared with placebo (RR, 0.81; 95% CI, 0.67 to 0.98). In the subgroup analyses, the use of SGLT-2 inhibitor and GLP-1 agonist was associated with a lower risk of stroke in those with high HbA1c (≥8.0) and low-risk of cardiovascular disease, respectively. Conclusion SGLT-2 inhibitors and GLP-1 agonists were shown to be beneficial for stroke prevention in patients with type 2 diabetes mellitus.

Published
2024
Full Text
View/download PDF

17. Initial Combination Therapy in Type 2 Diabetes

Author

Ji Yoon Kim and Nam Hoon Kim

Subjects
diabetes mellitus, type 2, drug therapy, combination, glycemic control, hypoglycemic agents, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Type 2 diabetes (T2D) is a progressive disease in which it is challenging to achieve long-term durable glycemic control. However, intensive glycemic control is crucial for preventing diabetes-related complications. Previous studies showed that monotherapy with a stepwise add-on approach was seldom effective for long-term durable glycemic control. Combination therapy, which refers to the use of two or more drugs to control hyperglycemia, has multiple benefits, including the ability to target a variety of pathophysiological processes underlying hyperglycemia. In clinical trials, initial combination therapy showed better glycemic control than monotherapy or a stepwise approach. Emerging evidence indicates that initial combination therapy is associated with preserved β-cell function and fewer complications in T2D. However, cost-effectiveness and adverse events with combination therapy are issues that should be considered. Therefore, initial combination therapy is an important option for patients with T2D that clinicians should consider with a view toward balancing benefits and potential harms. In this review, we summarize the literature addressing initial combination therapy in T2D, and we suggest optimal strategies based on clinical situations and patient characteristics.

Published
2024
Full Text
View/download PDF

18. Determining sex differences in drug combinations targeting aortic valve myofibroblast activation using an artificial intelligence derived platform

Subjects
Artificial intelligence, Drug therapy, Combination, Machine learning, Heart valve diseases, Physical fitness, Artificial intelligence, Health
Abstract

2024 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- According to news reporting based on a preprint abstract, our journalists obtained [...]

Published
2024

19. Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Subjects
United States. Food and Drug Administration, Drug therapy, Combination, Drugs, Drug approval, Alzheimer's disease -- Drug therapy, Physical fitness, Pharmaceutical industry, Health, Trulicity (Medication)
Abstract

2024 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but [...]

Published
2024

20. Novavax reports FDA placed clinical hold on IND for COVID-flu combo vaccine

Subjects
United States. Food and Drug Administration, Influenza vaccines, Drug therapy, Combination, Influenza, Clinical trials, Business, News, opinion and commentary
Abstract

Novavax announced that the U.S. Food and Drug Administration has placed a clinical hold on Novavax's Investigational New Drug, or IND, application for its COVID-19-Influenza Combination, or CIC, and stand-alone [...]

Published
2024

21. Research Results from Seth GSMC and KEM Hospital Update Knowledge of Paracetamol Therapy (A pharmacokinetic profiling study after single-tablet regimen of camylofin 50 mg and paracetamol 325 mg in healthy participants)

Subjects
Drug therapy, Combination, Physical fitness, Acetaminophen, Health
Abstract

2024 OCT 12 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on paracetamol therapy. According to news reporting from [...]

Published
2024

22. A Right Step Towards Tb Eradication

Subjects
Rifampin, Drug therapy, Combination, Drug resistance -- Care and treatment, Tuberculosis -- Care and treatment, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Byline: Ramesh Shankar The Union Health Ministry has recently approved introduction of the much anticipated BPaLM regimen for multi-drug-resistant tuberculosis (MDR-TB) as a highly effective and shorter treatment option. The [...]

Published
2024

23. Researchers Submit Patent Application, 'Drug Combination Of Fak Inhibitor And Immunogenic Cell Death Inducer And Use Thereof', for Approval (USPTO 20240285627)

Subjects
Biochemistry, Cell death, Antineoplastic agents -- Intellectual property, Immune response, Drug therapy, Combination, Monoclonal antibodies, Physical fitness, Antimitotic agents -- Intellectual property, Health
Abstract

2024 SEP 21 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- From Washington, D.C., NewsRx journalists report that a patent application by the [...]

Published
2024

26. Centre approves introduction of BPaLM treatment regimen for drug-resistant T

Subjects
Drug resistance in microorganisms -- Drug therapy, Drug therapy, Combination, Tuberculosis -- Drug therapy, Drug approval, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau The Union ministry of health and family welfare (MoHFW) has approved introduction of the much anticipated BPaLM regimen consisting of four-drug combination -- bedaquiline, pretomanid, linezolid and [...]

Published
2024

27. Drug combination prediction for cancer treatment using disease-specific drug response profiles and single-cell transcriptional signatures (Updated August 14, 2024)

Subjects
Women -- Health aspects, Diseases -- Drug therapy, Drug therapy, Combination, Genetic transcription, Health, Women's issues/gender studies
Abstract

2024 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- According to news reporting based on a preprint abstract, our journalists obtained the following [...]

Published
2024

28. MDC recommends retail prices for anti-diabetes combinations of empagliflozin

Subjects
Boehringer Ingelheim GmbH -- Intellectual property, Sitagliptin, Dapagliflozin, Diabetes therapy -- Prices and rates, Drug therapy, Combination, Pharmaceutical industry -- Intellectual property, Company pricing policy, Pharmaceuticals and cosmetics industries
Abstract

Byline: Gireesh Babu The Multidisciplinary Committee (MDC) of experts with the National Pharmaceutical Pricing Authority (NPPA) has recommended retail price of combinations containing diabetes drug empagliflozin, for which patent for [...]

Published
2024

29. New Antiarrhythmic Agents Findings Reported from University of Belgrade [Oxorhenium(V) Complexes With Pyridinedicarboxylic Ligands: Synthesis, Density Functional Theory Calculations, and Drug Combination Study]

Subjects
University of Belgrade, Pyridine, Anti-arrhythmia drugs, Drug therapy, Combination, Density functionals, Physical fitness
Abstract

2024 AUG 10 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Current study results on Drugs and Therapies - Antiarrhythmic Agents have been […]

Published
2024

30. Merck to discontinue phase 3 KeyVibe-008 trial of fixed-dose combination of vibostolimab and pembrolizumab in patients with extensive-stage SCLC

Subjects
Merck Research Laboratories, Drug therapy, Combination, Chemotherapy, Lung cancer, Cancer -- Chemotherapy, Pharmaceutical industry, Pharmaceuticals and cosmetics industries, Keytruda (Medication) -- Dosage and administration
Abstract

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the phase 3 KeyVibe-008 trial based on the recommendation of an independent Data Monitoring Committee [...]

Published
2024

31. Merck to discontinue Phase 3 KeyVibe-008 trial based on recommendation of DMC

Subjects
Merck Research Laboratories, Drug therapy, Combination, Chemotherapy, Lung cancer, Cancer -- Chemotherapy, Pharmaceutical industry, Business, News, opinion and commentary
Abstract

Merck announced the discontinuation of the Phase 3 KeyVibe-008 trial based on the recommendation of an independent Data Monitoring Committee. The trial is evaluating the investigational fixed-dose combination of vibostolimab, [...]

Published
2024

32. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study

Author

Jun Sung Moon, Il Rae Park, Sang Soo Kim, Hye Soon Kim, Nam Hoon Kim, Sin Gon Kim, Seung Hyun Ko, Ji Hyun Lee, Inkyu Lee, Bo Kyeong Lee, and Kyu Chang Won

Subjects
cardiovascular diseases, diabetes mellitus, type 2, drug therapy, combination, ezetimibe, rosuvastatin calcium, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Background To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM). Methods This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk

Published
2023
Full Text
View/download PDF

33. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

Author

Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, and Kun-Ho Yoon

Subjects
dapagliflozin, diabetes mellitus, type 2, dipeptidyl-peptidase iv inhibitors, drug therapy, combination, metformin, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Background This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. Methods In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998). Results Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P

Published
2023
Full Text
View/download PDF

34. Four everyday food and drink items you should never mix with medication -including dairy; Food including cheese, grapefruit and wine can have a big impact if mixed with normal remedies like statins and even paracetamol

Subjects
Tetracycline -- Complications and side effects, Statins -- Complications and side effects, Drug therapy, Combination, Tetracyclines -- Complications and side effects, Acetaminophen -- Complications and side effects, Hypertension -- Complications and side effects, General interest, News, opinion and commentary
Abstract

Byline: By, Ben Hurst The dangers of combining medications with supplements are well-known, but the potential for food to impact medication effectiveness is often overlooked, researchers warn. Eating certain foods [...]

Published
2024

35. BRIO-1 study results show renewed hope for medical presbyopia correction

Author

Koetting, Cecelia and Yeu, Elizabeth

Subjects
Presbyopia -- Care and treatment, Drug therapy, Combination, Health
Abstract

Results of the BRIO-I study, the first of 2 phase 3 clinical trials of Brimochol PF (carbachol/brimonidine tartrate; Visus Therapeutics), a topical, fixed-dose combination for the treatment of presbyopia, have [...]

Published
2023

36. Research Reports from Croatian Institute of Transfusion Medicine Provide New Insights into Pseudomonas aeruginosa (In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and ...)

Subjects
Drug therapy, Combination, Blood transfusion, Imipenem, Physical fitness, Pseudomonas aeruginosa, Health
Abstract

2024 JUL 13 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Fresh data on Pseudomonas aeruginosa are presented in a new report. According [...]

Published
2024

38. Studies from Indian Institute of Technology Roorkee Update Current Data on Breast Cancer (Folate Functionalized Multifunctional Cuo@phbv@pda Nanoplatform for Ph-responsive Dual Drug Delivery and Ros-driven Apoptosis In Breast Cancer)

Subjects
Oncology, Experimental, Women -- Health aspects, Drugs -- Vehicles, Folic acid, Drug therapy, Combination, Apoptosis, Cancer -- Research, Breast cancer, Drug delivery systems, Health, Women's issues/gender studies
Abstract

2024 JUN 27 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Oncology - Breast Cancer is the subject of a report. According [...]

Published
2024

39. Study Findings from Janssen Pharmaceutical Companies of Johnson & Johnson Provide New Insights into Endothelin Receptor Antagonists (Bioequivalence and the Food Effect of Macitentan/tadalafil 10/20 Fixed-dose Combination Tablets Versus the Use ...)

Subjects
Johnson & Johnson, Endothelin -- Dosage and administration, Drug therapy, Combination, Physical fitness, Pharmaceutical industry, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Endothelin Receptor Antagonists have been [...]

Published
2024

40. Researchers at Sirjan University of Technology Release New Data on Anticancer Agents (The Role of Hydrogen Bonds On the Stability of Anticancer Drug Compounds Tg/uracil, Tg/5-fluorouracil and Tg/gimeracil)

Subjects
Hydrogen, Antineoplastic agents, Drug therapy, Combination, Physical fitness, Hydrogen bonding, Antimitotic agents, Health
Abstract

2024 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Data detailed on Drugs and Therapies - Anticancer Agents have been presented. [...]

Published
2024

42. Moderna Announces Good Results From Trial of Combo COVID/Flu Vaccine

Subjects
Influenza vaccines, Drug therapy, Combination, Clinical trials, Health
Abstract

HealthDay News — An experimental vaccine that could offer one-stop prevention for both COVID-19 and influenza is showing positive results among older adults in trials, maker Moderna announced Monday. The [...]

Published
2024

43. FDA Approves First Generics of Heart Failure Combo Drug Entresto

Author

Ernst, Diana

Subjects
Generic drugs, Drug therapy, Combination, Valsartan, Drug approval, Heart, Cardiac patients -- Drug therapy, Heart failure -- Drug therapy, Health
Abstract

The Food and Drug Administration (FDA) has approved the first generics of https://www.empr.com/drug/entresto/ (sacubitril and valsartan; Novartis) tablets. The combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II [...]

Published
2024

46. Orchid Pharma gets DCGI approval to manufacture & market antibiotic drug combination of cefepime and enmetazobactam

Subjects
Urinary tract infections -- Drug therapy, Bacterial pneumonia -- Drug therapy, Drug therapy, Combination, Pneumonia -- Drug therapy, Drug approval, Antibiotics, Pharmaceuticals and cosmetics industries
Abstract

Byline: Our Bureau Chennai-based Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity active pharmaceutical ingredient (API), [...]

Published
2024

48. NPPA revises ceiling price of asthma inhaler drug combination in suo-moto correction

Subjects
Respiratory agents, Drug therapy, Combination, Asthma, Pharmaceuticals and cosmetics industries
Abstract

Byline: Gireesh Babu The National Pharmaceutical Pricing Authority (NPPA) has revised the ceiling price of asthma inhaler drug combination formoteral 6 mcg and budesonide 400 mcg dry power inhaler (DPI) [...]

Published
2024

49. Otsuka Ends Development of Combo Drug for Agitation in Alzheimer Disease

Author

Ernst, Diana

Subjects
Alzheimer's disease -- Drug therapy, Diseases -- Drug therapy, Drug therapy, Combination, Health
Abstract

Otsuka Pharmaceuticals has ended the development of AVP-786 for the treatment of agitation associated with dementia due to Alzheimer disease. AVP-786 is a combination of deudextromethorphan hydrobromide, an uncompetitive NMDA [...]

Published
2024

50. Taiho Oncology Announces Decitabine and Cedazuridine to be Included in NIH Precision Medicine Trials

Subjects
Gene mutations -- Genetic aspects, Drug therapy, Combination, Enzyme inhibitors -- Product development, Business, News, opinion and commentary
Abstract

Drug combination part of next-generation trials targeting specific genetic mutations in patients with myelodysplastic syndromes and acute myeloid leukemia PRINCETON, N.J., Jan. 14, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a [...]

Published
2025

Catalog

Books, media, physical & digital resources
See catalog results